Restoration and targeting of aberrant neurotransmitters in Parkinson's disease therapeutics
D Yadav, P Kumar - Neurochemistry international, 2022 - Elsevier
Neurotransmitters are considered as a fundamental regulator in the process of neuronal
growth, differentiation and survival. Parkinson's Disease (PD) occurs due to extensive …
growth, differentiation and survival. Parkinson's Disease (PD) occurs due to extensive …
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing
V Cesaroni, F Blandini, S Cerri - Expert Opinion on Therapeutic …, 2022 - Taylor & Francis
Introduction Parkinson's disease (PD) is the second most common neurodegenerative
disease after Alzheimer's disease. PD patients exhibit a classic spectrum of motor …
disease after Alzheimer's disease. PD patients exhibit a classic spectrum of motor …
[HTML][HTML] Circuit Mechanisms of L-DOPA-Induced Dyskinesia (LID)
K Yang, X Zhao, C Wang, C Zeng, Y Luo… - Frontiers in …, 2021 - frontiersin.org
l-DOPA is the criterion standard of treatment for Parkinson disease. Although it alleviates
some of the Parkinsonian symptoms, long-term treatment induces l-DOPA–induced …
some of the Parkinsonian symptoms, long-term treatment induces l-DOPA–induced …
The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in …
SR Cohen, ML Terry, M Coyle, E Wheelis… - Pharmacology …, 2022 - Elsevier
Parkinson's disease (PD) is a progressive, neurodegenerative movement disorder caused
by loss of nigrostriatal dopamine (DA) neurons. DA replacement therapy using L-3, 4 …
by loss of nigrostriatal dopamine (DA) neurons. DA replacement therapy using L-3, 4 …
[HTML][HTML] Histological correlates of neuroanatomical changes in a rat model of levodopa-induced dyskinesia based on voxel-based morphometry
X Zhang, W Chen, Y Wu, W Zeng, Y Yuan… - Frontiers in Aging …, 2021 - frontiersin.org
Long-term therapy with levodopa (L-DOPA) in patients with Parkinson's disease (PD) often
triggers motor complications termed as L-DOPA-induced dyskinesia (LID). However, few …
triggers motor complications termed as L-DOPA-induced dyskinesia (LID). However, few …
[HTML][HTML] AMPK-mediated autophagy pathway activation promotes ΔFosB degradation to improve levodopa-induced dyskinesia
K Liu, Z Zhang, Y Xu, Y Wu, P Lian, Z Ma, Z Tang… - Cellular …, 2024 - Elsevier
Background Parkinson's disease patients on chronic levodopa often suffer from motor
complications, which tend to reduce their quality of life. Levodopa-induced dyskinesia (LID) …
complications, which tend to reduce their quality of life. Levodopa-induced dyskinesia (LID) …
[HTML][HTML] Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice
YT Huang, YW Chen, TY Lin, JC Chen - Neurobiology of Disease, 2024 - Elsevier
A common adverse effect of Parkinson's disease (PD) treatment is L-dopa-induced
dyskinesia (LID). This condition results from both dopamine (DA)-dependent and DA …
dyskinesia (LID). This condition results from both dopamine (DA)-dependent and DA …
Pathological cell assembly dynamics in a striatal MSN network model
A Correa, A Ponzi, VM Calderón… - Frontiers in Computational …, 2024 - frontiersin.org
Under normal conditions the principal cells of the striatum, medium spiny neurons (MSNs),
show structured cell assembly activity patterns which alternate sequentially over …
show structured cell assembly activity patterns which alternate sequentially over …
[HTML][HTML] Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia
BA Kochoian, C Bure, SM Papa - Cells, 2023 - mdpi.com
A large body of work during the past several decades has been focused on therapeutic
strategies to control L-DOPA-induced dyskinesias (LIDs), common motor complications of …
strategies to control L-DOPA-induced dyskinesias (LIDs), common motor complications of …
Fenobam modulates distinct electrophysiological mechanisms for regulating excessive gamma oscillations in the striatum of dyskinetic rats
P Wang, W Dai, H Liu, H Liu, Y Xu - Experimental Neurology, 2024 - Elsevier
Gamma oscillations have been frequently observed in levodopa-induced dyskinesia (LID),
manifest as broadband (60-120 Hz) and narrowband (80-110 Hz) gamma activity in cortico …
manifest as broadband (60-120 Hz) and narrowband (80-110 Hz) gamma activity in cortico …